EQS-Adhoc: Biotest AG publishes preliminary business figures - 2024 forecasts partially exceeded

 

Ad-hoc RELEASE

Announcement according to Article 17 European Market Abuse Regulation (MAR)

 Biotest publishes preliminary business figures - 2024 forecasts partially exceeded

Dreieich, 26 February 2025: According to preliminary and unaudited figures, the Biotest Group generated revenue of € 726.2 million in the 2024 financial year, compared € 684.6 million in the previous year (+6.1%). This means that the revenues achieved are above the forecast low single-digit revenue growth. This includes the share of revenue from technology disclosure and development services with Grifols S.A.

The expected cash flow from operating activities was expected to be in the negative mid-double-digit million range. With a positive cash flow from operating activities of € 62.0 million, the expectation was significantly exceeded.

The Biotest Group achieved EBIT of € 94.5 million in the 2024 financial year after € 143.5 million in the previous year. The EBIT achieved is therefore at the upper end of the forecast range of € 80 million to € 100 million.

For the year 2024, a return on capital employed (ROCE) of 5-8% was expected. ROCE amounted to 7.9% for the 2024 financial year after 12.3% in 2023.

The aforementioned preliminary and unaudited figures for the Biotest Group are calculated in accordance with IFRS.

Biotest will publish the final figures for the 2024 financial year and the annual report on March 31, 2025.
 

Biotest Aktiengesellschaft
Board of Management

 

Biotest AG

Landsteinerstr. 5

D-63303 Dreieich

www.biotest.com
 

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

 

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been part of the Grifols Group, Barcelona, Spain (www.grifols.com).
 

IR contact

Dr. Monika Baumann (Buttkereit)

phone: +49-6103-801-4406
email: ir@biotest.com

 

PR contact

Dirk Neumüller

phone: +49-6103-801-269
email: pr@biotest.com

 

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

 

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Contact:
Martin Möller
Chief Financial Officer
Biotest AG
Landsteinerstr. 5
63303 Dreieich
Tel. +40 6103 801 2999
Fax: +49 6103 801 767
martin.moeller@biotest.com